Literature DB >> 20166763

Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.

Evan T Brower1, Arne Schön, Ernesto Freire.   

Abstract

Naturally occurring genetic variability across HIV-1 subtypes causes amino acid polymorphisms in encoded HIV-1 proteins including the envelope glycoproteins associated with viral entry. The effects of amino acid polymorphisms on the mechanism of HIV-1 entry into cells, a process initiated by the binding of the viral envelope glycoprotein gp120 to the cellular CD4 receptor, are largely unknown. In this study, we demonstrate that amino acid polymorphisms affect the structural stability and domain cooperativity of gp120 and that those differences are reflected in the binding mechanism of the viral envelope glycoprotein to the cell surface receptor and coreceptor. Moreover, subtype differences also affect the binding behavior of experimental HIV cell entry inhibitors. While gp120-A has a slightly lower denaturation temperature than gp120-B, the most notable stability difference is that for gp120-B the van't Hoff to calorimetric enthalpy ratio (DeltaH(vH)/DeltaH) is 0.95 whereas for gp120-A is 0.6, indicative of more cooperative domain/domain interactions in gp120-B, as this protein more closely approaches a two-state transition. Isothermal titration calorimetry demonstrates that CD4 and 17b (a surrogate antibody for the chemokine coreceptor) exhibit 7- and 3-fold weaker binding affinities for gp120-A. The binding of these proteins as well as that of the experimental entry inhibitor NBD-556 induces smaller conformational changes in gp120-A as evidenced by significantly smaller binding enthalpies and binding entropies. Together, these results describe the effects of gp120 polymorphisms on binding to host cell receptors and emphasize that guidelines for developing future entry inhibitors must recognize and deal with genomic differences between HIV strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166763      PMCID: PMC2840190          DOI: 10.1021/bi1000933

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults.

Authors:  G Becker-Pergola; P Kataaha; L Johnston-Dow; S Fung; J B Jackson; S H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

Review 2.  Protease inhibition in African subtypes of HIV-1.

Authors:  Adrián Velázquez-Campoy; Sonia Vega; Erin Fleming; Usman Bacha; Yasien Sayed; Heini W Dirr; Ernesto Freire
Journal:  AIDS Rev       Date:  2003 Jul-Sep       Impact factor: 2.500

3.  Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Authors:  Qian Zhao; Liying Ma; Shibo Jiang; Hong Lu; Shuwen Liu; Yuxian He; Nathan Strick; Nouri Neamati; Asim Kumar Debnath
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

4.  The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.

Authors:  David A van de Vijver; Annemarie M J Wensing; Gioacchino Angarano; Birgitta Asjö; Claudia Balotta; Enzo Boeri; Ricardo Camacho; Marie-Laure Chaix; Dominique Costagliola; Andrea De Luca; Inge Derdelinckx; Zehava Grossman; Osamah Hamouda; Angelos Hatzakis; Robert Hemmer; Andy Hoepelman; Andrzej Horban; Klaus Korn; Claudia Kücherer; Thomas Leitner; Clive Loveday; Eilidh MacRae; Irina Maljkovic; Carmen de Mendoza; Laurence Meyer; Claus Nielsen; Eline L M Op de Coul; Vidar Ormaasen; Dimitris Paraskevis; Luc Perrin; Elisabeth Puchhammer-Stöckl; Lidia Ruiz; Mika Salminen; Jean-Claude Schmit; Francois Schneider; Rob Schuurman; Vincent Soriano; Grzegorz Stanczak; Maja Stanojevic; Anne-Mieke Vandamme; Kristel Van Laethem; Michela Violin; Karin Wilbe; Sabine Yerly; Maurizio Zazzi; Charles A B Boucher
Journal:  J Acquir Immune Defic Syndr       Date:  2006-03       Impact factor: 3.731

5.  HIV-1 subtype as a determinant of disease progression.

Authors:  Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

6.  Structure-based prediction of binding affinities and molecular design of peptide ligands.

Authors:  I Luque; E Freire
Journal:  Methods Enzymol       Date:  1998       Impact factor: 1.600

7.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

8.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

9.  Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

Authors:  Evan T Brower; Usman M Bacha; Yuko Kawasaki; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2008-02-28       Impact factor: 2.817

10.  Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

Authors:  Deenan Pillay; A Sarah Walker; Diana M Gibb; Anita de Rossi; Steve Kaye; Mounir Ait-Khaled; Maria Muñoz-Fernandez; Abdel Babiker
Journal:  J Infect Dis       Date:  2002-08-09       Impact factor: 5.226

View more
  10 in total

1.  Ligand binding analysis and screening by chemical denaturation shift.

Authors:  Arne Schön; Richard K Brown; Burleigh M Hutchins; Ernesto Freire
Journal:  Anal Biochem       Date:  2013-08-29       Impact factor: 3.365

2.  Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen.

Authors:  Leopold Kong; David E Lee; Rameshwar U Kadam; Tong Liu; Erick Giang; Travis Nieusma; Fernando Garces; Netanel Tzarum; Virgil L Woods; Andrew B Ward; Sheng Li; Ian A Wilson; Mansun Law
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

Review 3.  Thermodynamics-based drug design: strategies for inhibiting protein-protein interactions.

Authors:  Arne Schön; Sonia Y Lam; Ernesto Freire
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

4.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

5.  Optimization of CD4/gp120 inhibitors by thermodynamic-guided alanine-scanning mutagenesis.

Authors:  Yingyun Liu; Arne Schön; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

6.  Three easy pieces.

Authors:  Arne Schön; Ernesto Freire
Journal:  Biochim Biophys Acta       Date:  2015-12-09

7.  Binding Thermodynamics to Intrinsically Disordered Protein Domains.

Authors:  Arne Schön; Ernesto Freire
Journal:  Methods Mol Biol       Date:  2020

8.  A flavonoid, luteolin, cripples HIV-1 by abrogation of tat function.

Authors:  Rajeev Mehla; Shalmali Bivalkar-Mehla; Ashok Chauhan
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

9.  Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.

Authors:  Max Lataillade; Nannan Zhou; Samit R Joshi; Sangil Lee; David A Stock; George J Hanna; Mark Krystal
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.